hrp0084p3-958 | GH & IGF | ESPE2015

The Correlation between the Increase in IGF1 24 h after the First Injection of GH and the Improved Growth

Miyako Kenichi , Mushimoto Yuichi , Kawano Atsuko

Background: IGF1 is a biomarker of GH, and is often used to titrate the dose of GH therapy. However, IGF1 production is regulated by not only GH but also other factors.Objective and hypotheses: We investigated whether the increase in IGF1 at several time points after the commencement of GH therapy could be a predictive factor for the improved growth.Method: We studied 45 pre-pubertal patients with GH deficiency (GHD) that had conti...

hrp0084p3-946 | GH & IGF | ESPE2015

The Correlation between the Increase in IGF1 and the Growth Improvement Induced by GH Treatment in Short Children Born Small for Gestational Age

Hattori Atsushi , Eto Junya , Kawano Atsuko , Miyako Kenichi

Background: IGF1 is an important marker of GH treatment and is used to titrate the GH dose.Objective and hypotheses: We report the correlation between the GH treatment induced increase in IGF1 and growth improvement in short children born small for gestational age (SGA).Method: We recruited 13 pre-pubertal SGA children (eight boys, five girls) who received GH treatment. Eight continued treatment for >2 years. We retrospectively...

hrp0097p2-35 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

A case of congenital central hypothyroidism with complete growth hormone deficiency caused by a novel nonsense mutation in the IGSF1 gene.

Miyako Kenichi , Furuzono Miwa , Tsukada Hiroko , Makimura Mika , Shibata Nao , Nagasaki Keisuke

The Ig superfamily member 1 (IGSF1) gene encodes a plasma membrane immunoglobulin superfamily glycoprotein, that is highly expressed in Rathke’s pouch and the adult pituitary gland and testis. It is now known that a loss-of-function mutation in this gene causes X-linked syndromic disorders including congenital central hypothyroidism, macroorchidism, prolactin deficiency, partial and transient growth hormone (GH) deficiency, disharmonious pubertal develo...

hrp0097p1-10 | Adrenals and HPA Axis | ESPE2023

Endocrinological, genetic and immunological features of a long-term survivor with MIRAGE syndrome

Furuzono Miwa , Makimura Mika , Miyako Kenichi , Tanase-Nakao Kanako , Narumi Satoshi , Hagiwara Hidetoshi , Mitsui-Sekinaka Kanako , Moriya Kunihiko , Imai Kohsuke

MIRAGE syndrome is characterized by myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes and enteropathy. It was established in 2016 as a new syndromic disorder caused by a gain-of-function mutation in the SAMD9 gene, which encodes a protein that suppresses cell proliferation. Due to the poor life prognosis, there are few reports on the long-term survival. Therefore, we herein report the clinical course of a 24-year-old male patient...

hrp0089p2-p273 | Growth & Syndromes P2 | ESPE2018

Seventeen-year Observation in a Japanese Female Case of Tatton-Brown-Rahman Syndrome: An Overgrowth Syndrome with Intellectual Disability

Miyoshi Yoko , Yamamoto Keiko , Nakano Yukako , Yamamoto Kenichi , Kubota Takuo , Ozono Keiichi

Background: Advances in genetic analysis techniques has greatly contributed to recent discovery of causative genes associated with overgrowth with intellectual disability (OGID). Tatton-Brown-Rahman syndrome (TBRS) (OMIM #615879) was one of them, characterized by tall stature, a distinctive facial appearance, and intellectual disability. This syndrome was first reported in 2014. Thus, long-term clinical courses are unknown. We present our Japanese case with OGID who was diagno...

hrp0089p2-p196 | Fetal, Neonatal Endocrinology and Metabolism P2 | ESPE2018

Prematurity of 23 or Less Weeks’ Gestation is a Risk for Transient Late-Onset Hyperglycemia in Neonates

Yamauchi Takeru , Sugie Manabu , Takasawa Kei , Imamura Masatoshi , Kashimada Kenichi

Background: Appropriate management for hyperglycemia is essential in preterm infants, because hyperglycemia increase the risk for intracranial hemorrhage, sepsis, retinopathy of prematurity, impairing long outcome to mortality and morbidity. In general, transient neonatal hyperglycemia is frequently observed during glucose infusion therapy, and it may not require interventions other than reducing glucose infusion. On the other hand, extremely preterm infants (EPIs GA <28 w...

hrp0092p1-168 | Bone, Growth Plate and Mineral Metabolism (1) | ESPE2019

Genotype-Phenotype Characteristics in Four Families of Type II Collagenopathy in Our Hospital

Yamamoto Kenichi , Kubota Takuo , Takeyari Shinji , Nakano Yukako , Nakayama Hirofumi , Fujiwara Makoto , Ohata Yasuhisa , Kitaoka Taichi , Miyoshi Yoko , Ozono Keiichi

Type II collagenopathy is a generic name of the skeletal dysplasia caused by COL2A1 gene, such as achondrogenesis type II, spondyloepiphyseal dysplasia (SEDC), spondyloepimetaphyseal dysplasia (SEMD). Since this is a rare disease, genotype-phenotype characteristics is still unclear. Here, we describe the genotype-phenotype characteristics of four families of type II collagenopathy in our hospital. Family 1: the proband was 2-year-old girl. She showed severe short stat...

hrp0086p1-p138 | Bone &amp; Mineral Metabolism P1 | ESPE2016

Biochemical Parameters Associated with Serum Intact FGF23 Levels in Patients with X-Linked Hypophosphatemic Rickets

Kubota Takuo , Yamamoto Keiko , Miyata Kei , Takeyari Shinji , Yamamoto Kenichi , Nakayama Hirofumi , Fujiwara Makoto , Kitaoka Taichi , Takakuwa Satoshi , Ozono Keiichi

Background: Fibroblast growth factor 23 (FGF23) decreases renal phosphate reabsorption and serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels. X-linked hypophosphatemic rickets (XLH) is caused by mutations in the PHEX gene and accompanied by decreased serum inorganic phosphate (IP) and elevated serum FGF23 levels. Patients with XLH are generally treated with oral active vitamin D and phosphate, but some previous reports indicated that serum FGF23 levels increased with ...

hrp0092p1-406 | Pituitary, Neuroendocrinology and Puberty (2) | ESPE2019

Tolvaptan for Management of Intractable Salt and Water Imbalance in a Case with Suprasellar Tumor after Surgery

Yamaguchi Tomoe , Terashita Shintaro , Kinjo Kenichi , Fujisawa Yusuke , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: It is sometimes difficult to diagnose and manage fluid and electrolyte imbalance after surgery for hypothalamic/pituitary tumors. We present a pediatric case of severe SIADH successfully treated with tolvaptan after suprasellar tumor resection.Case: The case was 8-year-old girl with growth failure. She was found to have suprasellar tumor on CT scan when she accidentally fell down and hit her head. MRI suggest...

hrp0089p3-p301 | Pituitary, Neuroendocrinology and Puberty P3 | ESPE2018

A Case of Central Diabetes Insipidus Developed 4 Years after the Non-CNS-Risk Unifocal Bone Lesion of Langerhans Cell Histiocytosis

Nakatani Hisae , Miyai Kentaro , Takasawa Kei , Kashimada Kenichi , Morimoto Akira , Nagasawa Masayuki , Oshiba Akihiro

Background: Langerhans cell histiocytosis (LCH) is a rare disease with an incidence of less than 10 per million, and characterized by the clonal proliferation of pathogenic Langerhans cells. The clinical courses are diverse, ranging from spontaneously remitting single organ disease to life-threatening multisystem involvement. One of the serious complications of LCH is diabetes insipidus (DI), and patients with CNS-risk lesions had higher cumulative incidence of DI. On the othe...